The stock of Recursion Pharmaceuticals Inc (RXRX) has seen a 15.88% increase in the past week, with a -2.98% drop in the past month, and a -13.51% decrease in the past quarter. The volatility ratio for the week is 7.11%, and the volatility levels for the past 30 days are at 7.72% for RXRX. The simple moving average for the past 20 days is 10.47% for RXRX’s stock, with a -13.44% simple moving average for the past 200 days.
Is It Worth Investing in Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Right Now?
RXRX has 36-month beta value of 0.83. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 6 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for RXRX is 215.44M, and currently, short sellers hold a 23.38% ratio of that float. The average trading volume of RXRX on August 26, 2024 was 5.64M shares.
RXRX) stock’s latest price update
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) has seen a rise in its stock price by 6.26 in relation to its previous close of 7.35. However, the company has experienced a 15.88% gain in its stock price over the last five trading sessions. fool.com reported 2024-08-18 that Recursion Pharmaceuticals is merging with Exscientia. The new entity will have the backing of quite a few big names in pharma.
Analysts’ Opinion of RXRX
Many brokerage firms have already submitted their reports for RXRX stocks, with Morgan Stanley repeating the rating for RXRX by listing it as a “Equal-Weight.” The predicted price for RXRX in the upcoming period, according to Morgan Stanley is $8 based on the research report published on May 22, 2023 of the previous year 2023.
Needham, on the other hand, stated in their research note that they expect to see RXRX reach a price target of $17. The rating they have provided for RXRX stocks is “Buy” according to the report published on March 16th, 2023.
KeyBanc Capital Markets gave a rating of “Overweight” to RXRX, setting the target price at $20 in the report published on September 16th of the previous year.
RXRX Trading at 0.22% from the 50-Day Moving Average
After a stumble in the market that brought RXRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.38% of loss for the given period.
Volatility was left at 7.72%, however, over the last 30 days, the volatility rate increased by 7.11%, as shares sank -6.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -16.02% lower at present.
During the last 5 trading sessions, RXRX rose by +15.88%, which changed the moving average for the period of 200-days by +41.23% in comparison to the 20-day moving average, which settled at $7.04. In addition, Recursion Pharmaceuticals Inc saw -20.79% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RXRX starting from Borgeson Blake, who sale 11,447 shares at the price of $7.12 back on Aug 20 ’24. After this action, Borgeson Blake now owns 7,132,769 shares of Recursion Pharmaceuticals Inc, valued at $81,532 using the latest closing price.
Borgeson Blake, the Director of Recursion Pharmaceuticals Inc, proposed sale 11,447 shares at $7.12 during a trade that took place back on Aug 20 ’24, which means that Borgeson Blake is holding shares at $81,533 based on the most recent closing price.
Stock Fundamentals for RXRX
Current profitability levels for the company are sitting at:
- -8.24 for the present operating margin
- -0.26 for the gross margin
The net margin for Recursion Pharmaceuticals Inc stands at -7.62. The total capital return value is set at -0.59. Equity return is now at value -71.18, with -51.98 for asset returns.
Based on Recursion Pharmaceuticals Inc (RXRX), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -8.36. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -5712.15.
Currently, EBITDA for the company is -317.6 million with net debt to EBITDA at 1.07. When we switch over and look at the enterprise to sales, we see a ratio of 35.81. The receivables turnover for the company is 19.48for trailing twelve months and the total asset turnover is 0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.07.
Conclusion
To put it simply, Recursion Pharmaceuticals Inc (RXRX) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
